TY  - JOUR
JF  - Kidney International Reports
A1  - Boeckhaus, Jan
A1  - Gale, Daniel P
A1  - Simon, James
A1  - Ding, Jie
A1  - Zhang, Yanqin
A1  - Bergmann, Carsten
A1  - Turner, A Neil
A1  - Hall, Matthew
A1  - Sayer, John A
A1  - Srivastava, Shalabh
A1  - Kang, Hee Gyung
A1  - Cerkauskaite-Kerpauskiene, Agne
A1  - Gillion, Valentine
A1  - Claes, Kathleen J
A1  - Krueger, Bastian
A1  - de Fallois, Jonathan
A1  - Walden, Ulrike
A1  - Choi, Mira
A1  - Schueler, Markus
A1  - Mueller, Roman-Ulrich
A1  - Todorova, Polina
A1  - Hohenstein, Bernd
A1  - Zeisberg, Michael
A1  - Friede, Tim
A1  - Knebelmann, Bertrand
A1  - Halbritter, Jan
A1  - Gross, Oliver
SN  - 2468-0249
UR  - https://doi.org/10.1016/j.ekir.2024.09.014
N1  - © 2024 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
IS  - 12
SP  - 3490
VL  - 9
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Urology & Nephrology
KW  -  albuminuria
KW  -  Alport syndrome
KW  -  COL4
KW  -  dapagliflozin
KW  -  empagliflozin
KW  -  kidney failure
KW  -  SGLT2 INHIBITORS
KW  -  EMPAGLIFLOZIN
KW  -  DAPAGLIFLOZIN
KW  -  INSIGHTS
ID  - discovery10205788
N2  - Introduction: Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated specifically in larger cohorts. Methods: This observational, multicenter, international study (NCT02378805) assessed 112 patients with AS after start of SGLT2i. The study's primary end point was change of albuminuria in albumin/g creatinine from the start of therapy. Results: Compared to randomized trials investigating the effect of SGLT2i in CKD, the adult patients in this study were younger (aged 38 ± 14 years) and had a better estimated glomerular filtration rate (eGFR, 63 ± 35 ml/min per 1.73 m2; n = 98). Maximum follow-up was 32 months. Compared to baseline, at the first 3 follow-up visits (months 1 to 3, 4 to 8, and 9 to 15) after initiation of SGLT2i therapy, a significant reduction of albuminuria in mg albumin/g creatinine (>30%) was observed. Mean loss of eGFR was 9 ± 12 ml/min per 1.73 m2 almost 1 year after initiation of SGLT2i therapy (n = 35). At a total of 71 patient-years at risk, 0.24 adverse events (AEs) per patient-year on SGLT2i were reported. Conclusion: This study indicates that, additive to renin-angiotensin system (RAS)-inhibition (RASi), SGLT2i have the potential to reduce the amount of albuminuria in patients with AS. Future studies are needed to investigate the long-term effects of SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in albuminuria translates to a delay in kidney failure (KF).
PB  - ELSEVIER SCIENCE INC
TI  - SGLT2-Inhibition in Patients With Alport Syndrome
EP  - 3500
AV  - public
Y1  - 2024/12//
ER  -